本帖最后由 老马 于 2012-1-13 21:20 编辑 & [$ {0 Q7 [. m0 p f
, h: y% |- V; N9 t: m
爱必妥和阿瓦斯丁的比较
) [6 I1 U8 T6 L1 c( _
- w* \$ l! C1 c2 {% H8 Mhttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/
& Q: p/ w1 X8 Q5 n
1 G" b: c8 j3 I R# X
5 u9 p4 C* @4 O% z6 e. ]+ d
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/+ x& r2 u6 ^/ Y. [. y J3 X1 C
==================================================
# A+ m: G% B6 X/ XOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
3 _; d& }8 R4 [" G- A# q; e7 {) cPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
* p% y$ S' c! ?3 Z, _9 x0 IResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
% A$ a. d5 p, L: Z8 U2 y7 \2 N# q
|